US pharmaceutical company Eli Lilly has crossed the milestone of one trillion dollars in market value, driven by the exceptional sales of its groundbreaking obesity drugs. It has become the first drug manufacturer to join the exclusive club typically dominated by major technology companies.
According to an international news agency report, the company’s more than 35 percent growth this year was largely due to the strong performance of its obesity drug segment. Eli Lilly’s medicines Mounjaro (for type 2 diabetes) and Zepbound (for obesity) have become among the world’s best selling drugs, allowing the company to surpass Novo Nordisk.
Experts say that the success is significantly attributed to the drug forglipran, an oral obesity medication that is easy for patients to use. At the same time, the company rapidly expanded its production and distribution network, strengthening its position in the market.
Reports indicate that in the recent quarter, Eli Lilly generated over 10 billion dollars in revenue from its obesity and diabetes products, which accounted for more than half of its total revenue of 17.6 billion dollars.
According to analysts, the current market value reflects investors’ confidence and indicates that the demand for obesity medications will remain strong in the future.
